E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/15/2014 in the Prospect News PIPE Daily.

Rexahn negotiates $20 million registered direct offering of its units

Offering sells units of one common share and one quarter-share warrant

By Devika Patel

Knoxville, Tenn., Jan. 15 - Rexahn Pharmaceuticals, Inc. said it plans a registered direct offering of units to raise $20 million. Roth Capital Partners is the lead agent, and H.C. Wainwright & Co., LLC is the co-placement agent.

The company will sell about 19.05 million units of one common share and one quarter-share warrant at $1.05 per unit, with each whole warrant exercisable at $1.28 for five years.

The strike price is a 10.35% premium to the Jan. 14 closing share price of $1.16.

Settlement is expected Jan. 21.

Proceeds will be used for development of clinical programs and other general corporate purposes.

Rexahn is a biopharmaceutical company based in Rockville, Md.

Issuer:Rexahn Pharmaceuticals, Inc.
Issue:Units of one common share and one quarter-share warrant
Amount:$20 million
Units:19.05 million (approximate)
Price:$1.05
Warrants:One quarter-share warrant per unit
Warrant expiration:Five years
Warrant strike price:$1.28
Agent:Roth Capital Partners (lead), H.C. Wainwright & Co., LLC (co-placement agent)
Pricing date:Jan. 15
Settlement date:Jan. 21
Stock symbol:NYSE: RNN
Stock price:$1.16 at close Jan. 14
Market capitalization:$151.12 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.